Novartis’ Investigational Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase III Clinical Trial
Novartis has announced positive results from the Phase III STEER clinical trial of its investigational therapy, intrathecal onasemnogene abeparvovec (OAV101 IT) in treatment-naïve patients with spinal muscular atrophy (SMA) Type 2. The pivotal study met …